Australia's most trusted
source of pharma news
Posted 24 September 2021 PM
Just when it seemed GSK CEO Emma Walmsley had escaped the chopping block following intense lobbying by hedge fund Elliott, a second activist investor group has bought up shares in the company and is also taking aim at her leadership.
While Bluebell Capital Partners is relatively small in terms of assets managed - it is big on pressure, having recently helped topple the CEO of French food giant Danone.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.